No title
Lung transplantation (LTx) remains the only curative treatment for patients with end-stage lung disease, yet long-term outcomes remain inferior to those of other solid organ transplantations, with a 5-year survival below 70%. Major contributors to this limited outcome include primary graft dysfunction (PGD), the leading cause of early mortality, chronic lung allograft dysfunction (CLAD), and low u
